CORD-19:12d35c12218f230c49f4dc892814ba9f1037f251 / 53433-54077 JSONTXT

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T17","span":{"begin":0,"end":644},"obj":"Sentence"}],"text":"Accumulating evidence from our laboratory and others support the notion that a critical component of any future CD8 T cell vaccine against highly virulent respiratory viruses must be the capacity to (1) promote robust expansion of naïve precursor T cells reactive with viral antigenic peptides; (2) allow a high frequency of these virus-specific effector T cells to survive over time as memory T cells; (3) allow high numbers of these memory cells to persist in the lung parenchyma and airways in the absence of persisting antigen; and (4) to retain high effector function in order to provide optimal surveillance against subsequent infections."}

{"project":"CORD-19-Sentences","denotations":[{"id":"T84720","span":{"begin":0,"end":644},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Accumulating evidence from our laboratory and others support the notion that a critical component of any future CD8 T cell vaccine against highly virulent respiratory viruses must be the capacity to (1) promote robust expansion of naïve precursor T cells reactive with viral antigenic peptides; (2) allow a high frequency of these virus-specific effector T cells to survive over time as memory T cells; (3) allow high numbers of these memory cells to persist in the lung parenchyma and airways in the absence of persisting antigen; and (4) to retain high effector function in order to provide optimal surveillance against subsequent infections."}

{"project":"Epistemic_Statements","denotations":[{"id":"T130","span":{"begin":0,"end":644},"obj":"Epistemic_statement"}],"text":"Accumulating evidence from our laboratory and others support the notion that a critical component of any future CD8 T cell vaccine against highly virulent respiratory viruses must be the capacity to (1) promote robust expansion of naïve precursor T cells reactive with viral antigenic peptides; (2) allow a high frequency of these virus-specific effector T cells to survive over time as memory T cells; (3) allow high numbers of these memory cells to persist in the lung parenchyma and airways in the absence of persisting antigen; and (4) to retain high effector function in order to provide optimal surveillance against subsequent infections."}

{"project":"CORD-19-PD-UBERON","denotations":[{"id":"T71","span":{"begin":466,"end":481},"obj":"Body_part"},{"id":"T72","span":{"begin":466,"end":470},"obj":"Body_part"},{"id":"T73","span":{"begin":471,"end":481},"obj":"Body_part"}],"attributes":[{"id":"A71","pred":"uberon_id","subj":"T71","obj":"http://purl.obolibrary.org/obo/UBERON_0008946"},{"id":"A72","pred":"uberon_id","subj":"T72","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A73","pred":"uberon_id","subj":"T73","obj":"http://purl.obolibrary.org/obo/UBERON_0000353"}],"text":"Accumulating evidence from our laboratory and others support the notion that a critical component of any future CD8 T cell vaccine against highly virulent respiratory viruses must be the capacity to (1) promote robust expansion of naïve precursor T cells reactive with viral antigenic peptides; (2) allow a high frequency of these virus-specific effector T cells to survive over time as memory T cells; (3) allow high numbers of these memory cells to persist in the lung parenchyma and airways in the absence of persisting antigen; and (4) to retain high effector function in order to provide optimal surveillance against subsequent infections."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T171","span":{"begin":633,"end":643},"obj":"Disease"},{"id":"T2311","span":{"begin":633,"end":643},"obj":"Disease"}],"attributes":[{"id":"A171","pred":"mondo_id","subj":"T171","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A14749","pred":"mondo_id","subj":"T2311","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"Accumulating evidence from our laboratory and others support the notion that a critical component of any future CD8 T cell vaccine against highly virulent respiratory viruses must be the capacity to (1) promote robust expansion of naïve precursor T cells reactive with viral antigenic peptides; (2) allow a high frequency of these virus-specific effector T cells to survive over time as memory T cells; (3) allow high numbers of these memory cells to persist in the lung parenchyma and airways in the absence of persisting antigen; and (4) to retain high effector function in order to provide optimal surveillance against subsequent infections."}